NZ545995A - Alpha, beta-unsaturated sulfoxides for treating proliferative disorders - Google Patents
Alpha, beta-unsaturated sulfoxides for treating proliferative disordersInfo
- Publication number
- NZ545995A NZ545995A NZ545995A NZ54599504A NZ545995A NZ 545995 A NZ545995 A NZ 545995A NZ 545995 A NZ545995 A NZ 545995A NZ 54599504 A NZ54599504 A NZ 54599504A NZ 545995 A NZ545995 A NZ 545995A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ethene
- methyl
- sulfinyl
- compound
- chlorophenyl
- Prior art date
Links
- 230000002062 proliferating effect Effects 0.000 title claims 5
- 150000003462 sulfoxides Chemical class 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims abstract 49
- 238000000034 method Methods 0.000 claims abstract 9
- 238000002360 preparation method Methods 0.000 claims abstract 8
- 230000004223 radioprotective effect Effects 0.000 claims abstract 7
- -1 for example Substances 0.000 claims abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 49
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 45
- 150000003839 salts Chemical class 0.000 claims 26
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 21
- 229920002554 vinyl polymer Polymers 0.000 claims 18
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 15
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 14
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 12
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 230000005865 ionizing radiation Effects 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 210000001185 bone marrow Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 230000000394 mitotic effect Effects 0.000 claims 7
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 239000007795 chemical reaction product Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229960001338 colchicine Drugs 0.000 claims 2
- 239000013256 coordination polymer Substances 0.000 claims 2
- 230000001120 cytoprotective effect Effects 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 2
- 229940041033 macrolides Drugs 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- 229960001156 mitoxantrone Drugs 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 238000010926 purge Methods 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- SKPKVJINHLRDOD-UHFFFAOYSA-N 1-(ethenylsulfinylmethyl)-4-fluorobenzene Chemical compound Fc1ccc(CS(=O)C=C)cc1 SKPKVJINHLRDOD-UHFFFAOYSA-N 0.000 claims 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 229910014033 C-OH Inorganic materials 0.000 claims 1
- 229910014570 C—OH Inorganic materials 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 208000001708 Dupuytren contracture Diseases 0.000 claims 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000004362 Penile Induration Diseases 0.000 claims 1
- 208000020758 Peyronie disease Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000016738 bone Paget disease Diseases 0.000 claims 1
- 208000011803 breast fibrocystic disease Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- SMWJPJLZIVEXKQ-UHFFFAOYSA-N ethenylsulfinylmethylbenzene Chemical compound C=CS(=O)CC1=CC=CC=C1 SMWJPJLZIVEXKQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 229940011051 isopropyl acetate Drugs 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940124444 chemoprotective agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/06—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52052303P | 2003-11-14 | 2003-11-14 | |
| PCT/US2004/037293 WO2005046599A2 (en) | 2003-11-14 | 2004-11-08 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ545995A true NZ545995A (en) | 2009-04-30 |
Family
ID=34590471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ545995A NZ545995A (en) | 2003-11-14 | 2004-11-08 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7744889B2 (enExample) |
| EP (1) | EP1689706B1 (enExample) |
| JP (1) | JP5196787B2 (enExample) |
| KR (1) | KR20060109871A (enExample) |
| AU (1) | AU2004289281C1 (enExample) |
| CA (1) | CA2546495C (enExample) |
| DK (1) | DK1689706T3 (enExample) |
| ES (1) | ES2621802T3 (enExample) |
| HU (1) | HUE032523T2 (enExample) |
| IL (1) | IL174426A (enExample) |
| NZ (1) | NZ545995A (enExample) |
| WO (1) | WO2005046599A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1740530B8 (en) * | 2004-03-16 | 2017-03-01 | Temple University - Of The Commonwealth System of Higher Education | Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders |
| EP1841420B1 (en) * | 2005-01-05 | 2011-12-07 | Temple University - Of The Commonwealth System of Higher Education | Treatment of drug-resistant proliferative disorders |
| US8106033B2 (en) * | 2005-03-11 | 2012-01-31 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| US20100080843A1 (en) * | 2005-06-30 | 2010-04-01 | The Research Foundation of the State University Of New York at Albany | Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis |
| WO2010075026A2 (en) * | 2008-12-16 | 2010-07-01 | Onconova Therapeutics Inc | Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human |
| GB201010359D0 (en) * | 2010-06-21 | 2010-08-04 | Univ Nottingham | Compounds for treating proliferative disorders |
| EP2486923B1 (en) * | 2011-02-11 | 2015-09-09 | Dr. Felix Jäger und Dr. Stefan Drinkuth Laborgemeinschaft OHG | Histone deacetylase (HDAC) inhibiting compounds and method of making same |
| CN110776447A (zh) | 2012-09-20 | 2020-02-11 | 坦普尔大学 | 取代的烷基二芳基衍生物、制备方法和用途 |
| JP2016523830A (ja) * | 2013-05-07 | 2016-08-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 放射線緩和薬学的配合物 |
| CN104892471B (zh) * | 2015-05-15 | 2020-03-27 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有蛋白酪氨酸激酶抑制活性的物质、其制备方法及用途 |
| US10383831B2 (en) * | 2015-08-03 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
| CN106432011B (zh) * | 2016-09-18 | 2018-11-02 | 中国医学科学院放射医学研究所 | 一类具有辐射防护作用的新化合物、其制备方法及其药物应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3865867A (en) * | 1967-06-19 | 1975-02-11 | Monsanto Co | Meta-bifunctional benzenes |
| US3975435A (en) * | 1974-03-06 | 1976-08-17 | Givaudan Corporation | Substituted cinnamanilides |
| GB1527109A (en) * | 1974-12-28 | 1978-10-04 | Asahi Chemical Ind | Cephalosporin derivatives and process for preparing same |
| JPH05262733A (ja) * | 1992-03-23 | 1993-10-12 | Sapporo Breweries Ltd | 含硫黄化合物，その製造法及びそれを有効成分とする抗潰瘍剤 |
| US5523302A (en) * | 1993-11-24 | 1996-06-04 | The Du Pont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| CN1287783C (zh) * | 1997-05-14 | 2006-12-06 | 阿特罗吉尼克斯公司 | 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用 |
| CZ299718B6 (cs) * | 1997-10-03 | 2008-10-29 | Temple University - Of The Commonwealth System Ofhigher Education | Styrylsulfonová sloucenina a farmaceutický prostredek ji obsahující |
| US6548553B2 (en) * | 1997-10-03 | 2003-04-15 | Temple University-Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| US6201154B1 (en) * | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
| US6762207B1 (en) * | 1999-04-02 | 2004-07-13 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| JP4596651B2 (ja) * | 1999-04-02 | 2010-12-08 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | （ｅ）−スチリルスルホン抗癌剤 |
| AU3381399A (en) * | 1999-04-02 | 2000-10-23 | Temple University - Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| US6117364A (en) * | 1999-05-27 | 2000-09-12 | Nalco/Exxon Energy Chemicals, L.P. | Acid corrosion inhibitor |
| WO2000077169A2 (en) * | 1999-06-16 | 2000-12-21 | Temple University - Of The Commonwealth System Of Higher Education | (z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors |
| US6767926B1 (en) * | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| AU780844B2 (en) * | 1999-10-12 | 2005-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6486210B2 (en) * | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
| US6541475B2 (en) * | 2000-04-14 | 2003-04-01 | Temple University - Of The Commonwealth System Of Higher Education | α, β-unsaturated sulfones for treating proliferative disorders |
| WO2002028828A1 (en) * | 2000-10-05 | 2002-04-11 | Temple University - Of The Commonwealth System Of Higher Education | Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| EP1493913B1 (en) * | 2000-10-12 | 2005-12-28 | Yamaha Hatsudoki Kabushiki Kaisha | Fuel gas mixer |
| US6833480B2 (en) * | 2001-02-27 | 2004-12-21 | Temple University - Of The Commonwealth System Of Higher Education | (Z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| JP4302986B2 (ja) * | 2001-02-28 | 2009-07-29 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法 |
| CA2439255C (en) * | 2001-02-28 | 2011-01-04 | Temple University Of The Commonwealth System Of Higher Education | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| MXPA04008356A (es) * | 2002-02-28 | 2005-09-12 | Univ Temple | (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas con un grupo amino y en la posicion 4 para tratar trastornos poliferativos. |
| EP1740530B8 (en) * | 2004-03-16 | 2017-03-01 | Temple University - Of The Commonwealth System of Higher Education | Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders |
| US8106033B2 (en) * | 2005-03-11 | 2012-01-31 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
-
2004
- 2004-11-08 US US10/574,993 patent/US7744889B2/en not_active Expired - Lifetime
- 2004-11-08 AU AU2004289281A patent/AU2004289281C1/en not_active Expired
- 2004-11-08 HU HUE04816944A patent/HUE032523T2/en unknown
- 2004-11-08 DK DK04816944.5T patent/DK1689706T3/da active
- 2004-11-08 JP JP2006539731A patent/JP5196787B2/ja not_active Expired - Fee Related
- 2004-11-08 KR KR1020067007327A patent/KR20060109871A/ko not_active Ceased
- 2004-11-08 CA CA2546495A patent/CA2546495C/en not_active Expired - Lifetime
- 2004-11-08 WO PCT/US2004/037293 patent/WO2005046599A2/en not_active Ceased
- 2004-11-08 NZ NZ545995A patent/NZ545995A/en not_active IP Right Cessation
- 2004-11-08 EP EP04816944.5A patent/EP1689706B1/en not_active Expired - Lifetime
- 2004-11-08 ES ES04816944.5T patent/ES2621802T3/es not_active Expired - Lifetime
-
2006
- 2006-03-20 IL IL174426A patent/IL174426A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004289281A1 (en) | 2005-05-26 |
| JP2007513877A (ja) | 2007-05-31 |
| US20060280746A1 (en) | 2006-12-14 |
| US7744889B2 (en) | 2010-06-29 |
| DK1689706T3 (da) | 2017-04-03 |
| IL174426A (en) | 2012-01-31 |
| WO2005046599A3 (en) | 2005-10-06 |
| HUE032523T2 (en) | 2017-09-28 |
| WO2005046599A2 (en) | 2005-05-26 |
| KR20060109871A (ko) | 2006-10-23 |
| CA2546495C (en) | 2012-10-09 |
| AU2004289281C1 (en) | 2011-12-08 |
| EP1689706A4 (en) | 2007-11-14 |
| JP5196787B2 (ja) | 2013-05-15 |
| IL174426A0 (en) | 2006-08-01 |
| CA2546495A1 (en) | 2005-05-26 |
| EP1689706A2 (en) | 2006-08-16 |
| ES2621802T3 (es) | 2017-07-05 |
| AU2004289281B2 (en) | 2011-05-26 |
| EP1689706B1 (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ545995A (en) | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | |
| TWI855000B (zh) | Ｓｔｉｎｇ促效化合物 | |
| JP2007511504A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2014512364A5 (enExample) | ||
| CA2447779A1 (en) | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | |
| JP2013516393A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| CA2545942A1 (en) | Aryl imidazoles and their use as anti-cancer agents | |
| JP2011526917A5 (enExample) | ||
| CA2290744A1 (en) | Cyclic diamine compounds and medicine containing the same | |
| EP3194380A1 (en) | Benzyl substituted indazoles as bub1 kinase inhibitors | |
| RU2003103780A (ru) | Соединения фенилпиридазина и содержащие их лекарственные средства | |
| JP2017529353A (ja) | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 | |
| JP2016525104A5 (enExample) | ||
| CZ20033189A3 (cs) | Kombinované léčivo pro léčbu nádorových onemocnění | |
| JPWO2020173935A5 (enExample) | ||
| JP2021522244A (ja) | チューブリン重合阻害活性及び免疫調節特性を有する化合物 | |
| JP2004504385A5 (enExample) | ||
| JP2008545803A5 (enExample) | ||
| RU2007147925A (ru) | Замещенные тетрагидрохинолины | |
| JPWO2019213570A5 (enExample) | ||
| KR101879992B1 (ko) | c-Myc/Max/DNA 복합체 형성을 억제하는 화합물 | |
| WO2018215282A1 (en) | Combination of bub1 and pi3k inhibitors | |
| WO2008076810A2 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2015 BY COMPUTER PACKAGES INC Effective date: 20141018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2016 BY COMPUTER PACKAGES INC Effective date: 20151020 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2017 BY COMPUTER PACKAGES INC Effective date: 20161018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2018 BY COMPUTER PACKAGES INC Effective date: 20171018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2019 BY COMPUTER PACKAGES INC Effective date: 20181018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2020 BY COMPUTER PACKAGES INC Effective date: 20191018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2021 BY COMPUTER PACKAGES INC Effective date: 20201020 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2022 BY COMPUTER PACKAGES INC Effective date: 20211017 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2023 BY COMPUTER PACKAGES INC Effective date: 20221017 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 NOV 2024 BY COMPUTER PACKAGES INC Effective date: 20231017 |
|
| EXPY | Patent expired |